Correction to: Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1

Okła, Karolina; Rajtak, Alicja; Czerwonka, Arkadiusz; Bobinski, M.; Wawruszak, Anna; Tarkowski, Rafał; Bednarek, Wiesława; Szumiło, Justyna; Kotarski, Jan

doi:10.1186/s12967-020-02431-8

Cited by 4 publications

(5 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be caused by the significant contribution of immune cell-derived sPD-L1 relative to tumor cell-derived sPD-L1 since immune cells also secrete PD-L1. 26 Okła et al 27 reported that PD-L1 expression was higher in immune cells infiltrating ovarian cancer tissue compared with tumor cells, and that sPD-L1 correlated with PD-L1 expression in immune cells in the blood. Keber et al 28 also found that sPD-L1 in the blood increased following resection of renal cancer, and that sPD-L1 levels correlated with PD-L1 mRNA expression in the blood.…”

Section: Discussionmentioning

confidence: 99%

“…This may be caused by the significant contribution of immune cell–derived sPD‐L1 relative to tumor cell–derived sPD‐L1 since immune cells also secrete PD‐L1 26 . Okła et al 27 . reported that PD‐L1 expression was higher in immune cells infiltrating ovarian cancer tissue compared with tumor cells, and that sPD‐L1 correlated with PD‐L1 expression in immune cells in the blood.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Soluble PD‐L1 predicts tumor response and immune‐related adverse events in patients with advanced melanoma treated with anti–PD‐1 antibodies

Oya,

Nakamura,

Shen

et al. 2024

The Journal of Dermatology

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) bring prognostic benefits to patients with malignancies. However, there is a substantial number of patients whose lesions are not improved by ICIs. In addition, ICIs may cause immune‐related adverse events (irAEs), which could lead to an unfavorable prognosis with fatal consequences. Therefore, we conducted a retrospective study to evaluate the utility of circulating sPD‐L1 (soluble programmed cell death 1 ligand 1) as a biomarker in patients with advanced melanoma treated with anti–PD‐1 (programmed cell death 1 protein) antibodies. Sera from 31 consecutive patients were prospectively collected before and after anti–PD‐1 antibody treatment and the serum level of sPD‐L1 was evaluated. We found that high sPD‐L1 levels before treatment were associated with better prognosis, and this association was observed only in patients with a low tumor burden. We also found that sPD‐L1 levels were elevated in patients who developed severe irAEs after treatment, and the patients with severe irAEs had significantly higher fluctuations in sPD‐L1 (delta sPD‐L1) than those without severe irAEs. Our study suggests that serum sPD‐L1 level is a useful biomarker to predict tumor response and irAE development in patients with advanced melanoma treated with anti–PD‐1 antibodies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Soluble PD‐L1 predicts tumor response and immune‐related adverse events in patients with advanced melanoma treated with anti–PD‐1 antibodies

Oya,

Nakamura,

Shen

et al. 2024

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Immune checkpoint analysis. SIGLEC15, TIGIT, CD274, HAVCR2, PDCD1, CTLA4, LAG3 and PDCD1LG2 were selected as immune checkpoint-relevant transcripts (24)(25)(26)(27)(28)(29), and all the expression values of these eight genes were extracted. The aforementioned analyses and R packages were implemented in R software (version 4.0.3) using the 'ggplot2' and 'pheatmap' packages (version 4.0.3) (30)(31)(32).…”

Section: Univariate Analysis Multivariate Cox Analysis and Nomogrammentioning

confidence: 99%

Identification and prognostic analysis of ferroptosis‑related gene HSPA5 to predict the progression of lung squamous cell carcinoma

Guo,

Feng,

Liu

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

Ferroptosis, an iron-dependent form of regulated cell death driven by excessive lipid peroxidation, is implicated in the development and therapeutic responses of cancer. However, the role of ferroptosis-related gene profiles in lung squamous cell carcinoma (LSCC) remains largely unknown. The present study aimed to identify the prognostic roles of ferroptosis-related genes in LSCC. Sequencing data from the Cancer Genome Atlas were analyzed and ferroptosis-related gene expression between tumor and para-tumor tissue was identified. The prognostic role of these genes was also assessed using Kaplan-Meier analyses and univariate and multivariate Cox proportional hazards regression model analyses. Immunological correlation, tumor stemness, drug sensitivity and the transcriptional differences of heat shock protein (HSP)A5 in LSCC were also analyzed. Thereafter, the expression of HSPA5 in 100 patients with metastatic LSCC was evaluated using immunohistochemistry (IHC) and the clinical significance of these markers with different risk factors was assessed. Of the 22 ferroptosis-related genes, the expression of HSPA5, HSPB1, glutathione peroxidase 4, Fanconi anemia complementation group D2, CDGSH iron sulfur domain 1, farnesyl-diphosphate farnesyltransferase 1, nuclear factor erythroid 2 like 2, solute carrier (SLC)1A5, ribosomal protein L8, nuclear receptor coactivator 4, transferrin receptor and SLC7A11 was significantly increased in LSCC compared with adjacent tissues. However, only high expression of HSPA5 was able to predict progression-free survival (PFS) and disease-free survival in LSCC. Although HSPA5 was also significantly elevated in patients with lung adenocarcinoma, HSPA5 expression did not predict the prognosis of patients with lung adenocarcinoma. Of note, a higher expression of HSPA5 was related to higher responses to chemotherapy but not to immunotherapy. In addition, HSPA5 expression was positively correlated with 'ferroptosis', 'cellular responses to hypoxia', 'tumor proliferation signature', 'G2M checkpoint', 'MYC targets' and 'TGFB'. IHC analysis also demonstrated that a high expression of HSPA5 in patients with metastatic LSCC in the study cohort was associated with shorter PFS and overall survival. In conclusion, the present study demonstrated that the expression of the ferroptosis-related gene HSPA5 may be a negative prognostic marker for LSCC.

show abstract

“…This discrepancy was also observed in renal cell carcinoma and diffuse large B-cell lymphoma 17,25 suggesting that soluble PD-L1/2 is not a simple alternative of tissue PD-L1/2 expression. Because the main resources of soluble PD-L1 would be myeloid cells but not tumor cells., [26][27][28] tumoral PD-L1 expression and serum sPD-L1 are not necessarily correlated. Since tissue PD-L1 (CPS and TPS) indicates the immune inhibition only in the effector site, soluble PD-L1 represents the comprehensive immune inhibition in the body including lymph nodes where T cells are educated.…”

Section: No Authormentioning

confidence: 99%

Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD‐L1 and PD‐L2

Sato,

Komatsuda,

Inoue

et al. 2024

Head & Neck

View full text Add to dashboard Cite

BackgroundPredictive biomarkers for nivolumab in recurrent or metastatic head and neck squamous cell carcinoma (RMHNSCC) have not yet been established.MethodsThe tumor proportion score (TPS), combined positive score (CPS), and soluble forms of programmed cell death ligand‐1 (PD‐L1) and programmed cell death ligand‐2 (PD‐L2) were retrospectively analyzed in patients with RMHNSCC treated with nivolumab.ResultsThe positivity rates for TPS (PD‐L1), CPS (PD‐L1), TPS (PD‐L2), and CPS (PD‐L2) were 73.8%, 78.2%, 56.4%, and 78.2%, respectively. Patients with high TPS (PD‐L1), CPS (PD‐L1), or CPS (PD‐L1 and PD‐L2) showed significantly prolonged progression‐free survival. Favorable overall survival was associated with high CPS (PD‐L1 and PD‐L2) and low soluble PD‐L1 and PD‐L2 levels. The expressions of tissue and soluble PD‐L1/2 were not correlated.ConclusionsOur study revealed that compared to PD‐L1 expression alone, dual expression of PD‐L1 and PD‐L2 in tissue or soluble form could be feasible biomarkers in patients with RMHNSCC who received nivolumab.

show abstract

Correction to: Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1

Abstract: An amendment to this paper has been published and can be accessed via the original article.

Cited by 4 publications

References 1 publication

Soluble PD‐L1 predicts tumor response and immune‐related adverse events in patients with advanced melanoma treated with anti–PD‐1 antibodies

Soluble PD‐L1 predicts tumor response and immune‐related adverse events in patients with advanced melanoma treated with anti–PD‐1 antibodies

Identification and prognostic analysis of ferroptosis‑related gene HSPA5 to predict the progression of lung squamous cell carcinoma

Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD‐L1 and PD‐L2

Contact Info

Product

Resources

About